1 6176 100 THE HISTONE H3 LYSINE-27 DEMETHYLASE JMJD3 LINKS INFLAMMATION TO INHIBITION OF POLYCOMB-MEDIATED GENE SILENCING. EPIGENETIC CHROMATIN MARKS RESTRICT THE ABILITY OF DIFFERENTIATED CELLS TO CHANGE GENE EXPRESSION PROGRAMS IN RESPONSE TO ENVIRONMENTAL CUES AND TO TRANSDIFFERENTIATE. POLYCOMB GROUP (PCG) PROTEINS MEDIATE GENE SILENCING AND REPRESS TRANSDIFFERENTIATION IN A MANNER DEPENDENT ON HISTONE H3 LYSINE 27 TRIMETHYLATION (H3K27ME3). HOWEVER, MACROPHAGES MIGRATED INTO INFLAMED TISSUES CAN TRANSDIFFERENTIATE, BUT IT IS UNKNOWN WHETHER INFLAMMATION ALTERS PCG-DEPENDENT SILENCING. HERE WE SHOW THAT THE JMJC-DOMAIN PROTEIN JMJD3 IS A H3K27ME DEMETHYLASE EXPRESSED IN MACROPHAGES IN RESPONSE TO BACTERIAL PRODUCTS AND INFLAMMATORY CYTOKINES. JMJD3 BINDS PCG TARGET GENES AND REGULATES THEIR H3K27ME3 LEVELS AND TRANSCRIPTIONAL ACTIVITY. THE DISCOVERY OF AN INDUCIBLE ENZYME THAT ERASES A HISTONE MARK CONTROLLING DIFFERENTIATION AND CELL IDENTITY PROVIDES A LINK BETWEEN INFLAMMATION AND REPROGRAMMING OF THE EPIGENOME, WHICH COULD BE THE BASIS FOR MACROPHAGE PLASTICITY AND MIGHT EXPLAIN THE DIFFERENTIATION ABNORMALITIES IN CHRONIC INFLAMMATION. 2007 2 4546 29 MUTANT P53 REGULATES ENHANCER-ASSOCIATED H3K4 MONOMETHYLATION THROUGH INTERACTIONS WITH THE METHYLTRANSFERASE MLL4. MONOMETHYLATION OF HISTONE H3 LYSINE 4 (H3K4ME1) IS ENRICHED AT ENHANCERS THAT ARE PRIMED FOR ACTIVATION AND THE LEVELS OF THIS HISTONE MARK ARE FREQUENTLY ALTERED IN VARIOUS HUMAN CANCERS. YET, HOW ALTERATIONS IN H3K4ME1 ARE ESTABLISHED AND THE CONSEQUENCES OF THESE EPIGENETIC CHANGES IN TUMORIGENESIS ARE NOT WELL UNDERSTOOD. USING CHIP-SEQ IN HUMAN COLON CANCER CELLS, WE DEMONSTRATE THAT MUTANT P53 DEPLETION RESULTS IN DECREASED H3K4ME1 LEVELS AT ACTIVE ENHANCERS THAT REVEAL A STRIKING COLOCALIZATION OF MUTANT P53 AND THE H3K4 MONOMETHYLTRANSFERASE MLL4 FOLLOWING CHRONIC TUMOR NECROSIS FACTOR ALPHA (TNFALPHA) SIGNALING. WE FURTHER REVEAL THAT MUTANT P53 FORMS PHYSIOLOGICAL ASSOCIATIONS AND DIRECT INTERACTIONS WITH MLL4 AND PROMOTES THE ENHANCER BINDING OF MLL4, WHICH IS REQUIRED FOR TNFALPHA-INDUCIBLE H3K4ME1 AND HISTONE H3 LYSINE 27 ACETYLATION (H3K27AC) LEVELS, ENHANCER-DERIVED TRANSCRIPT (ERNA) SYNTHESIS, AND MUTANT P53-DEPENDENT TARGET GENE ACTIVATION. COMPLEMENTARY IN VITRO STUDIES WITH RECOMBINANT CHROMATIN AND PURIFIED PROTEINS DEMONSTRATE THAT BINDING OF THE MLL3/4 COMPLEX AND H3K4ME1 DEPOSITION IS ENHANCED BY MUTANT P53 AND P300-MEDIATED ACETYLATION, WHICH IN TURN REFLECTS A MLL3/4-DEPENDENT ENHANCEMENT OF MUTANT P53 AND P300-DEPENDENT TRANSCRIPTIONAL ACTIVATION. COLLECTIVELY, OUR FINDINGS ESTABLISH A MECHANISM IN WHICH MUTANT P53 COOPERATES WITH MLL4 TO REGULATE ABERRANT ENHANCER ACTIVITY AND TUMOR-PROMOTING GENE EXPRESSION IN RESPONSE TO CHRONIC IMMUNE SIGNALING. 2018 3 2280 31 EPIGENETIC REGULATION IN DRUG ADDICTION. THE INTERACTION BETWEEN ENVIRONMENTAL SIGNALS AND GENES HAS NOW TAKEN ON A CLEAR MOLECULAR FORM AS DEMONSTRATED BY STABLE CHANGES IN CHROMATIN STRUCTURE. THESE CHANGES OCCUR THROUGH ACTIVATION OR REPRESSION OF SPECIFIC GENE PROGRAMMES BY A COMBINATION OF CHROMATIN REMODELLING, ACTIVATION AND ENZYMATIC MODIFICATION OF DNA AND HISTONES AS WELL AS NUCLEOSOMAL SUBUNIT EXCHANGE. RECENT RESEARCH INVESTIGATING THE MOLECULAR MECHANISMS CONTROLLING DRUG-INDUCED TRANSCRIPTIONAL, BEHAVIOURAL AND SYNAPTIC ACTIVITY HAS SHOWN A DIRECT ROLE FOR CHROMATIN REMODELLING--TERMED AS EPIGENETIC REGULATION--OF NEURONAL GENE PROGRAMMES AND SUBSEQUENT ADDICTIVE BEHAVIOUR ARISING FROM IT. RECENT DATA SUGGEST THAT REPEATED EXPOSURE TO CERTAIN DRUGS PROMOTES CHANGES IN LEVELS OF HISTONE ACETYLATION, PHOSPHORYLATION AND METHYLATION, TOGETHER WITH ALTERATIONS IN DNA METHYLATION LEVELS IN THE NEURONS OF THE BRAIN REWARD CENTRE, LOCALISED IN THE NUCLEUS ACCUMBENS (NAC) REGION OF THE LIMBIC SYSTEM. THE COMBINATION OF ACETYLATING, PHOSPHORYLATING AND METHYLATING H3 AND H4 HISTONE TAILS ALTER CHROMATIN COMPACTION THEREBY PROMOTING ALTERED LEVELS OF CELLULAR GENE EXPRESSION. HISTONE MODIFICATIONS, WHICH WEAKEN HISTONE INTERACTION WITH DNA OR THAT PROMOTE RECRUITMENT OF TRANSCRIPTIONAL ACTIVATING COMPLEXES, CORRELATE WITH PERMISSIVE GENE EXPRESSION. HISTONE DEACETYLATION, (WHICH STRENGTHEN HISTONE: DNA CONTACTS), OR HISTONE METHYLATION, (WHICH RECRUITS REPRESSIVE COMPLEXES TO CHROMATIN), PROMOTE A STATE OF TRANSCRIPTIONAL REPRESSION. USING ANIMAL MODELS, ACUTE COCAINE TREATMENT INCREASES H4 ACETYLATION AT ACUTELY REGULATED GENE PROMOTERS, WHEREAS H3 ACETYLATION APPEARS TO PREDOMINATE AT CHRONICALLY INDUCED PROMOTERS. CHRONIC COCAINE AND ALCOHOL TREATMENT ACTIVATE AND REPRESS MANY GENES SUCH AS FOSB, CDK5, AND BDNF, WHERE THEIR DYSREGULATION, AT THE CHROMATIN LEVEL, CONTRIBUTE TO THE DEVELOPMENT AND MAINTENANCE OF ADDICTION. FOLLOWING DRUG EXPOSURE, IT IS STILL UNKNOWN, HOWVER, HOW LONG THESE CHANGES IN CHROMATIN STRUCTURE PERSIST IN AFFECTING NEURONAL FUNCTION, BUT SOME DO SO FOR LIFE. 2012 4 2370 30 EPIGENETIC REGULATION OF THE ALTERNATIVELY ACTIVATED MACROPHAGE PHENOTYPE. ALTERNATIVELY ACTIVATED (M2) MACROPHAGES PLAY CRITICAL ROLES IN DIVERSE CHRONIC DISEASES, INCLUDING PARASITE INFECTIONS, CANCER, AND ALLERGIC RESPONSES. HOWEVER, LITTLE IS KNOWN ABOUT THE ACQUISITION AND MAINTENANCE OF THEIR PHENOTYPE. WE REPORT THAT M2-MACROPHAGE MARKER GENES ARE EPIGENETICALLY REGULATED BY RECIPROCAL CHANGES IN HISTONE H3 LYSINE-4 (H3K4) AND HISTONE H3 LYSINE-27 (H3K27) METHYLATION; AND THE LATTER METHYLATION MARKS ARE REMOVED BY THE H3K27 DEMETHYLASE JUMONJI DOMAIN CONTAINING 3 (JMJD3). WE FOUND THAT CONTINUOUS INTERLEUKIN-4 (IL-4) TREATMENT LEADS TO DECREASED H3K27 METHYLATION, AT THE PROMOTER OF M2 MARKER GENES, AND A CONCOMITANT INCREASE IN JMJD3 EXPRESSION. FURTHERMORE, WE DEMONSTRATE THAT IL-4-DEPENDENT JMJD3 EXPRESSION IS MEDIATED BY STAT6, A MAJOR TRANSCRIPTION FACTOR OF IL-4-MEDIATED SIGNALING. AFTER IL-4 STIMULATION, ACTIVATED STAT6 IS INCREASED AND BINDS TO CONSENSUS SITES AT THE JMJD3 PROMOTER. INCREASED JMJD3 CONTRIBUTES TO THE DECREASE OF H3K27 DIMETHYLATION AND TRIMETHYLATION (H3K27ME2/3) MARKS AS WELL AS THE TRANSCRIPTIONAL ACTIVATION OF SPECIFIC M2 MARKER GENES. THE DECREASE IN H3K27ME2/3 AND INCREASE IN JMJD3 RECRUITMENT WERE CONFIRMED BY IN VIVO STUDIES USING A SCHISTOSOMA MANSONI EGG-CHALLENGED MOUSE MODEL, A WELL-STUDIED SYSTEM KNOWN TO SUPPORT AN M2 PHENOTYPE. COLLECTIVELY, THESE DATA INDICATE THAT CHROMATIN REMODELING IS MECHANISTICALLY IMPORTANT IN THE ACQUISITION OF THE M2-MACROPHAGE PHENOTYPE. 2009 5 2910 28 GENE EXPRESSION PROFILING OF EPIGENETIC CHROMATIN MODIFICATION ENZYMES AND HISTONE MARKS BY CIGARETTE SMOKE: IMPLICATIONS FOR COPD AND LUNG CANCER. CHROMATIN-MODIFYING ENZYMES MEDIATE DNA METHYLATION AND HISTONE MODIFICATIONS ON RECRUITMENT TO SPECIFIC TARGET GENE LOCI IN RESPONSE TO VARIOUS STIMULI. THE KEY ENZYMES THAT REGULATE CHROMATIN ACCESSIBILITY FOR MAINTENANCE OF MODIFICATIONS IN DNA AND HISTONES, AND FOR MODULATION OF GENE EXPRESSION PATTERNS IN RESPONSE TO CIGARETTE SMOKE (CS), ARE NOT KNOWN. WE HYPOTHESIZE THAT CS EXPOSURE ALTERS THE GENE EXPRESSION PATTERNS OF CHROMATIN-MODIFYING ENZYMES, WHICH THEN AFFECTS MULTIPLE DOWNSTREAM PATHWAYS INVOLVED IN THE RESPONSE TO CS. WE HAVE, THEREFORE, ANALYZED CHROMATIN-MODIFYING ENZYME PROFILES AND VALIDATED BY QUANTITATIVE REAL-TIME PCR (QPCR). WE ALSO PERFORMED IMMUNOBLOT ANALYSIS OF TARGETED HISTONE MARKS IN C57BL/6J MICE EXPOSED TO ACUTE AND SUBCHRONIC CS, AND OF LUNGS FROM NONSMOKERS, SMOKERS, AND PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). WE FOUND A SIGNIFICANT INCREASE IN EXPRESSION OF SEVERAL CHROMATIN MODIFICATION ENZYMES, INCLUDING DNA METHYLTRANSFERASES, HISTONE ACETYLTRANSFERASES, HISTONE METHYLTRANSFERASES, AND SET DOMAIN PROTEINS, HISTONE KINASES, AND UBIQUITINASES. OUR QPCR VALIDATION DATA REVEALED A SIGNIFICANT DOWNREGULATION OF DNMT1, DNMT3A, DNMT3B, HDAC2, HDAC4, HAT1, PRMT1, AND AURKB WE IDENTIFIED TARGETED CHROMATIN HISTONE MARKS (H3K56AC AND H4K12AC), WHICH ARE INDUCED BY CS. THUS CS-INDUCED GENOTOXIC STRESS DIFFERENTIALLY AFFECTS THE EXPRESSION OF EPIGENETIC MODULATORS THAT REGULATE TRANSCRIPTION OF TARGET GENES VIA DNA METHYLATION AND SITE-SPECIFIC HISTONE MODIFICATIONS. THIS MAY HAVE IMPLICATIONS IN DEVISING EPIGENETIC-BASED THERAPIES FOR COPD AND LUNG CANCER. 2016 6 3189 27 HBX RELIEVES CHROMATIN-MEDIATED TRANSCRIPTIONAL REPRESSION OF HEPATITIS B VIRAL CCCDNA INVOLVING SETDB1 HISTONE METHYLTRANSFERASE. BACKGROUND & AIMS: MAINTENANCE OF THE COVALENTLY CLOSED CIRCULAR HBV DNA (CCCDNA) THAT SERVES AS A TEMPLATE FOR HBV TRANSCRIPTION IS RESPONSIBLE FOR THE FAILURE OF ANTIVIRAL THERAPIES. WHILE STUDIES IN CHRONIC HEPATITIS PATIENTS HAVE SHOWN THAT HIGH VIREMIA CORRELATES WITH HYPERACETYLATION OF CCCDNA-ASSOCIATED HISTONES, THE MOLECULAR MECHANISMS CONTROLLING CCCDNA STABILITY AND TRANSCRIPTIONAL REGULATION ARE STILL POORLY UNDERSTOOD. THIS STUDY AIMED TO DECIPHER THE ROLE OF CHROMATIN AND CHROMATIN MODIFIER PROTEINS ON HBV TRANSCRIPTION. METHODS: WE ANALYZED THE CHROMATIN STRUCTURE OF ACTIVELY TRANSCRIBED OR SILENCED CCCDNA BY INFECTING PRIMARY HUMAN HEPATOCYTES AND DIFFERENTIATED HEPARG CELLS WITH WILD-TYPE VIRUS OR VIRUS DEFICIENT (HBVX-) FOR THE EXPRESSION OF HEPATITIS B VIRUS X PROTEIN (HBX), THAT IS REQUIRED FOR HBV EXPRESSION. RESULTS: IN THE ABSENCE OF HBX, HBV CCCDNA WAS TRANSCRIPTIONALLY SILENCED WITH THE CONCOMITANT DECREASE OF HISTONE 3 (H3) ACETYLATION AND H3K4ME3, INCREASE OF H3 DI- AND TRI-METHYLATION (H3K9ME) AND THE RECRUITMENT OF HETEROCHROMATIN PROTEIN 1 FACTORS (HP1) THAT CORRELATE WITH CONDENSED CHROMATIN. SETDB1 WAS FOUND TO BE THE MAIN HISTONE METHYLTRANSFERASE RESPONSIBLE FOR THE DEPOSITION OF H3K9ME3 AND HBV REPRESSION. FINALLY, FULL TRANSCRIPTIONAL REACTIVATION OF HBVX- UPON HBX RE-EXPRESSION CORRELATED WITH AN INCREASE OF HISTONE ACETYLATION AND H3K4ME3, AND A CONCOMITANT DECREASE OF HP1 BINDING AND OF H3K9ME3 ON THE CCCDNA. CONCLUSION: UPON HBV INFECTION, CELLULAR MECHANISMS INVOLVING SETDB1-MEDIATED H3K9ME3 AND HP1 INDUCE SILENCING OF HBV CCCDNA TRANSCRIPTION THROUGH MODULATION OF CHROMATIN STRUCTURE. HBX IS ABLE TO RELIEVE THIS REPRESSION AND ALLOW THE ESTABLISHMENT OF ACTIVE CHROMATIN. 2015 7 1012 24 CIGARETTE SMOKE INDUCES DISTINCT HISTONE MODIFICATIONS IN LUNG CELLS: IMPLICATIONS FOR THE PATHOGENESIS OF COPD AND LUNG CANCER. CIGARETTE SMOKE (CS)-MEDIATED OXIDATIVE STRESS INDUCES SEVERAL SIGNALING CASCADES, INCLUDING KINASES, WHICH RESULTS IN CHROMATIN MODIFICATIONS (HISTONE ACETYLATION/DEACETYLATION AND HISTONE METHYLATION/DEMETHYLATION). WE HAVE PREVIOUSLY REPORTED THAT CS INDUCES CHROMATIN REMODELING IN PRO-INFLAMMATORY GENE PROMOTERS; HOWEVER, THE UNDERLYING SITE-SPECIFIC HISTONE MARKS FORMED IN HISTONES H3 AND H4 DURING CS EXPOSURE IN LUNGS IN VIVO AND IN LUNG CELLS IN VITRO, WHICH CAN EITHER DRIVE GENE EXPRESSION OR REPRESSION, ARE NOT KNOWN. WE HYPOTHESIZE THAT CS EXPOSURE IN MOUSE AND HUMAN BRONCHIAL EPITHELIAL CELLS (H292) CAN CAUSE SITE-SPECIFIC POSTTRANSLATIONAL HISTONE MODIFICATIONS (PTMS) THAT MAY PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF CS-INDUCED CHRONIC LUNG DISEASES. WE USED A BOTTOM-UP MASS SPECTROMETRY APPROACH TO IDENTIFY SOME POTENTIALLY NOVEL HISTONE MARKS, INCLUDING ACETYLATION, MONOMETHYLATION, AND DIMETHYLATION, IN SPECIFIC LYSINE AND ARGININE RESIDUES OF HISTONES H3 AND H4 IN MOUSE LUNGS AND H292 CELLS. WE FOUND THAT CS-INDUCED DISTINCT POSTTRANSLATIONAL HISTONE MODIFICATION PATTERNS IN HISTONE H3 AND HISTONE H4 IN LUNG CELLS, WHICH MAY BE CONSIDERED AS USABLE BIOMARKERS FOR CS-INDUCED CHRONIC LUNG DISEASES. THESE IDENTIFIED HISTONE MARKS (HISTONE H3 AND HISTONE H4) MAY PLAY AN IMPORTANT ROLE IN THE EPIGENETIC STATE DURING THE PATHOGENESIS OF SMOKING-INDUCED CHRONIC LUNG DISEASES, SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER. 2014 8 1315 34 DELTA FOSB MEDIATES EPIGENETIC DESENSITIZATION OF THE C-FOS GENE AFTER CHRONIC AMPHETAMINE EXPOSURE. THE MOLECULAR MECHANISMS UNDERLYING THE TRANSITION FROM RECREATIONAL DRUG USE TO CHRONIC ADDICTION REMAIN POORLY UNDERSTOOD. ONE MOLECULE IMPLICATED IN THIS PROCESS IS DELTAFOSB, A TRANSCRIPTION FACTOR THAT ACCUMULATES IN STRIATUM AFTER REPEATED DRUG EXPOSURE AND MEDIATES SENSITIZED BEHAVIORAL RESPONSES TO PSYCHOSTIMULANTS AND OTHER DRUGS OF ABUSE. THE DOWNSTREAM TRANSCRIPTIONAL MECHANISMS BY WHICH DELTAFOSB REGULATES DRUG-INDUCED BEHAVIORS ARE INCOMPLETELY UNDERSTOOD. WE REPORTED PREVIOUSLY THE CHROMATIN REMODELING MECHANISMS BY WHICH DELTAFOSB ACTIVATES THE EXPRESSION OF CERTAIN GENES; HOWEVER, THE MECHANISMS UNDERLYING DELTAFOSB-MEDIATED GENE REPRESSION REMAIN UNKNOWN. HERE, WE IDENTIFY C-FOS, AN IMMEDIATE EARLY GENE RAPIDLY INDUCED IN STRIATUM AFTER ACUTE PSYCHOSTIMULANT EXPOSURE, AS A NOVEL DOWNSTREAM TARGET THAT IS REPRESSED CHRONICALLY BY DELTAFOSB. WE SHOW THAT ACCUMULATION OF DELTAFOSB IN STRIATUM AFTER CHRONIC AMPHETAMINE TREATMENT DESENSITIZES C-FOS MRNA INDUCTION TO A SUBSEQUENT DRUG DOSE. DELTAFOSB DESENSITIZES C-FOS EXPRESSION BY RECRUITING HISTONE DEACETYLASE 1 (HDAC1) TO THE C-FOS GENE PROMOTER, WHICH, IN TURN, DEACETYLATES SURROUNDING HISTONES AND ATTENUATES GENE ACTIVITY. ACCORDINGLY, LOCAL KNOCK-OUT OF HDAC1 IN STRIATUM ABOLISHES AMPHETAMINE-INDUCED DESENSITIZATION OF THE C-FOS GENE. IN CONCERT, CHRONIC AMPHETAMINE INCREASES HISTONE H3 METHYLATION ON THE C-FOS PROMOTER, A CHROMATIN MODIFICATION ALSO KNOWN TO REPRESS GENE ACTIVITY, AS WELL AS EXPRESSION LEVELS OF THE H3 HISTONE METHYLTRANSFERASE, KMT1A (LYSINE METHYLTRANSFERASE 1A, FORMERLY SUV39H1). THIS STUDY REVEALS A NOVEL EPIGENETIC PATHWAY THROUGH WHICH DELTAFOSB MEDIATES DISTINCT TRANSCRIPTIONAL PROGRAMS THAT MAY ULTIMATELY ALTER BEHAVIORAL PLASTICITY TO CHRONIC AMPHETAMINE EXPOSURE. 2008 9 1652 38 DOPAMINE SIGNALING LEADS TO LOSS OF POLYCOMB REPRESSION AND ABERRANT GENE ACTIVATION IN EXPERIMENTAL PARKINSONISM. POLYCOMB GROUP (PCG) PROTEINS BIND TO AND REPRESS GENES IN EMBRYONIC STEM CELLS THROUGH LINEAGE COMMITMENT TO THE TERMINAL DIFFERENTIATED STATE. PCG REPRESSED GENES ARE COMMONLY CHARACTERIZED BY THE PRESENCE OF THE EPIGENETIC HISTONE MARK H3K27ME3, CATALYZED BY THE POLYCOMB REPRESSIVE COMPLEX 2. HERE, WE PRESENT IN VIVO EVIDENCE FOR A PREVIOUSLY UNRECOGNIZED PLASTICITY OF PCG-REPRESSED GENES IN TERMINALLY DIFFERENTIATED BRAIN NEURONS OF PARKISONIAN MICE. WE SHOW THAT ACUTE ADMINISTRATION OF THE DOPAMINE PRECURSOR, L-DOPA, INDUCES A REMARKABLE INCREASE IN H3K27ME3S28 PHOSPHORYLATION. THE INDUCTION OF THE H3K27ME3S28P HISTONE MARK SPECIFICALLY OCCURS IN MEDIUM SPINY NEURONS EXPRESSING DOPAMINE D1 RECEPTORS AND IS DEPENDENT ON MSK1 KINASE ACTIVITY AND DARPP-32-MEDIATED INHIBITION OF PROTEIN PHOSPHATASE-1. CHROMATIN IMMUNOPRECIPITATION (CHIP) EXPERIMENTS SHOWED THAT INCREASED H3K27ME3S28P WAS ACCOMPANIED BY REDUCED PCG BINDING TO REGULATORY REGIONS OF GENES. AN ANALYSIS OF THE GENOME WIDE DISTRIBUTION OF L-DOPA-INDUCED H3K27ME3S28 PHOSPHORYLATION BY CHIP SEQUENCING (CHIP-SEQ) IN COMBINATION WITH EXPRESSION ANALYSIS BY RNA-SEQUENCING (RNA-SEQ) SHOWED THAT THE INDUCTION OF H3K27ME3S28P CORRELATED WITH INCREASED EXPRESSION OF A SUBSET OF PCG REPRESSED GENES. WE FOUND THAT INDUCTION OF H3K27ME3S28P PERSISTED DURING CHRONIC L-DOPA ADMINISTRATION TO PARKISONIAN MICE AND CORRELATED WITH ABERRANT GENE EXPRESSION. WE PROPOSE THAT DOPAMINERGIC TRANSMISSION CAN ACTIVATE PCG REPRESSED GENES IN THE ADULT BRAIN AND THEREBY CONTRIBUTE TO LONG-TERM MALADAPTIVE RESPONSES INCLUDING THE MOTOR COMPLICATIONS, OR DYSKINESIA, CAUSED BY PROLONGED ADMINISTRATION OF L-DOPA IN PARKINSON'S DISEASE. 2014 10 2117 28 EPIGENETIC HISTONE METHYLATION MODULATES FIBROTIC GENE EXPRESSION. TGF-BETA1-INDUCED EXPRESSION OF EXTRACELLULAR MATRIX (ECM) GENES PLAYS A MAJOR ROLE IN THE DEVELOPMENT OF CHRONIC RENAL DISEASES SUCH AS DIABETIC NEPHROPATHY. ALTHOUGH MANY KEY TRANSCRIPTION FACTORS ARE KNOWN, MECHANISMS INVOLVING THE NUCLEAR CHROMATIN THAT MODULATE ECM GENE EXPRESSION REMAIN UNCLEAR. HERE, WE EXAMINED THE ROLE OF EPIGENETIC CHROMATIN MARKS SUCH AS HISTONE H3 LYSINE METHYLATION (H3KME) IN TGF-BETA1-INDUCED GENE EXPRESSION IN RAT MESANGIAL CELLS UNDER NORMAL AND HIGH-GLUCOSE (HG) CONDITIONS. TGF-BETA1 INCREASED THE EXPRESSION OF THE ECM-ASSOCIATED GENES CONNECTIVE TISSUE GROWTH FACTOR, COLLAGEN-ALPHA1[IOTA], AND PLASMINOGEN ACTIVATOR INHIBITOR-1. INCREASED LEVELS OF CHROMATIN MARKS ASSOCIATED WITH ACTIVE GENES (H3K4ME1, H3K4ME2, AND H3K4ME3), AND DECREASED LEVELS OF REPRESSIVE MARKS (H3K9ME2 AND H3K9ME3) AT THESE GENE PROMOTERS ACCOMPANIED THESE CHANGES IN EXPRESSION. TGF-BETA1 ALSO INCREASED EXPRESSION OF THE H3K4 METHYLTRANSFERASE SET7/9 AND RECRUITMENT TO THESE PROMOTERS. SET7/9 GENE SILENCING WITH SIRNAS SIGNIFICANTLY ATTENUATED TGF-BETA1-INDUCED ECM GENE EXPRESSION. FURTHERMORE, A TGF-BETA1 ANTIBODY NOT ONLY BLOCKED HG-INDUCED ECM GENE EXPRESSION BUT ALSO REVERSED HG-INDUCED CHANGES IN PROMOTER H3KME LEVELS AND SET7/9 OCCUPANCY. TAKEN TOGETHER, THESE RESULTS SHOW THE FUNCTIONAL ROLE OF EPIGENETIC CHROMATIN HISTONE H3KME IN TGF-BETA1-MEDIATED ECM GENE EXPRESSION IN MESANGIAL CELLS UNDER NORMAL AND HG CONDITIONS. PHARMACOLOGIC AND OTHER THERAPIES THAT REVERSE THESE MODIFICATIONS COULD HAVE POTENTIAL RENOPROTECTIVE EFFECTS FOR DIABETIC NEPHROPATHY. 2010 11 3357 33 HISTONE H3 LYSINE 9 DI-METHYLATION AS AN EPIGENETIC SIGNATURE OF THE INTERFERON RESPONSE. EFFECTIVE ANTIVIRAL IMMUNITY DEPENDS ON THE ABILITY OF INFECTED CELLS OR CELLS TRIGGERED WITH VIRUS-DERIVED NUCLEIC ACIDS TO PRODUCE TYPE I INTERFERON (IFN), WHICH ACTIVATES TRANSCRIPTION OF NUMEROUS ANTIVIRAL GENES. HOWEVER, DISPROPORTIONATELY STRONG OR CHRONIC IFN EXPRESSION IS A COMMON CAUSE OF INFLAMMATORY AND AUTOIMMUNE DISEASES. WE DESCRIBE AN EPIGENETIC MECHANISM THAT DETERMINES CELL TYPE-SPECIFIC DIFFERENCES IN IFN AND IFN-STIMULATED GENE (ISG) EXPRESSION IN RESPONSE TO EXOGENOUS SIGNALS. WE IDENTIFY DI-METHYLATION OF HISTONE H3 AT LYSINE 9 (H3K9ME2) AS A SUPPRESSOR OF IFN AND IFN-INDUCIBLE ANTIVIRAL GENE EXPRESSION. WE SHOW THAT LEVELS OF H3K9ME2 AT IFN AND ISG CORRELATE INVERSELY WITH THE SCOPE AND AMPLITUDE OF IFN AND ISG EXPRESSION IN FIBROBLASTS AND DENDRITIC CELLS. ACCORDINGLY, GENETIC ABLATION OR PHARMACOLOGICAL INACTIVATION OF LYSINE METHYLTRANSFERASE G9A, WHICH IS ESSENTIAL FOR THE GENERATION OF H3K9ME2, RESULTED IN PHENOTYPIC CONVERSION OF FIBROBLASTS INTO HIGHLY POTENT IFN-PRODUCING CELLS AND RENDERED THESE CELLS RESISTANT TO PATHOGENIC RNA VIRUSES. IN SUMMARY, OUR STUDIES IMPLICATE H3K9ME2 AND ENZYMES CONTROLLING ITS ABUNDANCE AS KEY REGULATORS OF INNATE ANTIVIRAL IMMUNITY. 2012 12 3362 32 HISTONE LYSINE DEMETHYLASE KDM5B MAINTAINS CHRONIC MYELOID LEUKEMIA VIA MULTIPLE EPIGENETIC ACTIONS. THE HISTONE LYSINE DEMETHYLASE KDM5 FAMILY IS IMPLICATED IN NORMAL DEVELOPMENT AND STEM CELL MAINTENANCE BY EPIGENETIC MODULATION OF HISTONE METHYLATION STATUS. DEREGULATION OF THE KDM5 FAMILY HAS BEEN REPORTED IN VARIOUS TYPES OF CANCERS, INCLUDING HEMATOLOGICAL MALIGNANCIES. HOWEVER, THEIR TRANSCRIPTIONAL REGULATORY ROLES IN THE CONTEXT OF LEUKEMIA REMAIN UNCLEAR. HERE, WE FIND THAT KDM5B IS STRONGLY EXPRESSED IN NORMAL CD34(+) HEMATOPOIETIC STEM/PROGENITOR CELLS AND CHRONIC MYELOID LEUKEMIA (CML) CELLS. KNOCKDOWN OF KDM5B IN K562 CML CELLS REDUCED LEUKEMIA COLONY-FORMING POTENTIAL. TRANSCRIPTOME PROFILING OF KDM5B KNOCKDOWN K562 CELLS REVEALED THE DEREGULATION OF GENES INVOLVED IN MYELOID DIFFERENTIATION AND TOLL-LIKE RECEPTOR SIGNALING. THROUGH THE INTEGRATION OF TRANSCRIPTOME AND CHIP-SEQ PROFILING DATA, WE SHOW THAT KDM5B IS ENRICHED AT THE BINDING SITES OF THE GATA AND AP-1 TRANSCRIPTION FACTOR FAMILIES, SUGGESTING THEIR COLLABORATIONS IN THE REGULATION OF TRANSCRIPTION. EVEN THOUGH THE BINDING OF KDM5B SUBSTANTIALLY OVERLAPPED WITH H3K4ME1 OR H3K4ME3 MARK AT GENE PROMOTERS, ONLY A SMALL SUBSET OF THE KDM5B TARGETS SHOWED DIFFERENTIAL EXPRESSION IN ASSOCIATION WITH THE HISTONE DEMETHYLATION ACTIVITY. BY CHARACTERIZING THE INTERACTING PROTEINS IN K562 CELLS, WE DISCOVERED THAT KDM5B RECRUITS PROTEIN COMPLEXES INVOLVED IN THE MRNA PROCESSING MACHINERY, IMPLYING AN ALTERNATIVE EPIGENETIC ACTION MEDIATED BY KDM5B IN GENE REGULATION. OUR STUDY HIGHLIGHTS THE ONCOGENIC FUNCTIONS OF KDM5B IN CML CELLS AND SUGGESTS THAT KDM5B IS VITAL TO THE TRANSCRIPTIONAL REGULATION VIA MULTIPLE EPIGENETIC MECHANISMS. 2020 13 6519 28 TRANSCRIPTIONAL AND EPIGENETIC REGULATION OF INTERLEUKIN-2 GENE IN ACTIVATED T CELLS BY MORPHINE. CHRONIC MORPHINE INHIBITS INTERLEUKIN-2 (IL-2) AT BOTH THE TRANSCRIPTIONAL AND PROTEIN SYNTHESIS LEVELS. THE MOLECULAR MECHANISMS BY WHICH MORPHINE DECREASES IL-2 ARE NOT FULLY UNDERSTOOD. THE PRODUCTION OF IL-2 IS TIGHTLY REGULATED BY SEVERAL TRANSCRIPTION FACTORS THAT BIND TO THE IL-2 PROMOTER. HEREIN, WE SHOW THAT CHRONIC MORPHINE TREATMENT RESULTS IN AN INCREASE IN CAMP LEVELS WITH A CONCURRENT UP-REGULATION OF THE CAMP INDUCIBLE REPRESSOR INDUCIBLE CAMP EARLY REPRESSOR (ICER)/CAMP RESPONSE ELEMENT MODULATOR (CREM) AND DOWN-REGULATION OF P-CAMP-RESPONSE ELEMENT-BINDING PROTEIN (CREB) IN ACTIVATED T CELLS. FURTHERMORE, ICER COMPETES FOR P-CREB BINDING TO THE CAMP-RESPONSIVE ELEMENTS (CRES) SITE. THIS LEADS TO THE UNCOUPLING OF CBP/P300 THEREBY ABROGATING IL-2 TRANSCRIPTION. OVEREXPRESSION OF EITHER ANTISENSE CREM OR CREB PLASMID RESCUED MORPHINE-INDUCED INHIBITION OF IL-2 PROMOTER ACTIVITY AND PROTEIN PRODUCTION. IN ADDITION, WE ALSO FOUND THAT CHRONIC MORPHINE TREATMENT INHIBITED THE ACETYLATION AND TRIMETHYLATION OF HISTONES AND DECREASED BOTH DNA DEMETHYLATION AND ACCESSIBILITY OF THE IL-2 PROMOTER. THESE FINDINGS SUGGEST THAT CHRONIC MORPHINE TREATMENT MAY FUNCTION THROUGH BOTH TRANSCRIPTIONAL AND EPIGENETIC MECHANISMS TO INHIBIT IL-2 PRODUCTION. 2007 14 2825 38 FLOW-DEPENDENT EPIGENETIC REGULATION OF IGFBP5 EXPRESSION BY H3K27ME3 CONTRIBUTES TO ENDOTHELIAL ANTI-INFLAMMATORY EFFECTS. RATIONALE: ATHEROSCLEROSIS IS A CHRONIC INFLAMMATORY AND EPIGENETIC DISEASE THAT IS INFLUENCED BY DIFFERENT PATTERNS OF BLOOD FLOW. HOWEVER, THE EPIGENETIC MECHANISM WHEREBY ATHEROPROTECTIVE FLOW CONTROLS ENDOTHELIAL GENE PROGRAMMING REMAINS ELUSIVE. HERE, WE INVESTIGATED THE POSSIBILITY THAT FLOW ALTERS ENDOTHELIAL GENE EXPRESSION THROUGH EPIGENETIC MECHANISMS. METHODS: EN FACE STAINING AND WESTERN BLOT WERE USED TO DETECT PROTEIN EXPRESSION. REAL-TIME PCR WAS USED TO DETERMINE RELATIVE GENE EXPRESSION. RNA-SEQUENCING OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS TREATED WITH SIRNA OF ENHANCER OF ZESTE HOMOLOG 2 (EZH2) OR LAMINAR FLOW WAS USED FOR TRANSCRIPTIONAL PROFILING. RESULTS: WE FOUND THAT TRIMETHYLATION OF HISTONE 3 LYSINE 27 (H3K27ME3), A REPRESSIVE EPIGENETIC MARK THAT ORCHESTRATES GENE REPRESSION, WAS REDUCED IN LAMINAR FLOW AREAS OF MOUSE AORTA AND FLOW-TREATED HUMAN ENDOTHELIAL CELLS. THE DECREASE OF H3K27ME3 PARALLELED A REDUCTION IN THE EPIGENETIC "WRITER"-EZH2, THE CATALYTIC SUBUNIT OF THE POLYCOMB REPRESSIVE COMPLEX 2 (PRC2). MOREOVER, LAMINAR FLOW DECREASED EXPRESSION OF EZH2 VIA MECHANOSENSITIVE MIR101. GENOME-WIDE TRANSCRIPTOME PROFILING STUDIES IN ENDOTHELIAL CELLS TREATED WITH EZH2 SIRNA AND FLOW REVEALED THE UPREGULATION OF NOVEL MECHANOSENSITIVE GENE IGFBP5 (INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 5), WHICH IS EPIGENETICALLY SILENCED BY H3K27ME3. FUNCTIONALLY, INHIBITION OF H3K27ME3 BY EZH2 SIRNA OR GSK126 (A SPECIFIC EZH2 INHIBITOR) REDUCED H3K27ME3 LEVELS AND MONOCYTE ADHESION TO ENDOTHELIAL CELLS. ADENOVIRAL OVEREXPRESSION OF IGFBP5 ALSO RECAPITULATED THE ANTI-INFLAMMATORY EFFECTS OF H3K27ME3 INHIBITION. MORE IMPORTANTLY, WE OBSERVED EZH2 UPREGULATION, AND IGFBP5 DOWNREGULATION, IN ADVANCED ATHEROSCLEROTIC PLAQUES FROM HUMAN PATIENTS. CONCLUSION: TAKEN TOGETHER, OUR FINDINGS REVEAL THAT ATHEROPROTECTIVE FLOW REDUCES H3K27ME3 AS A CHROMATIN-BASED MECHANISM TO AUGMENT THE EXPRESSION OF GENES THAT CONFER AN ANTI-INFLAMMATORY RESPONSE IN THE ENDOTHELIUM. OUR STUDY EXEMPLIFIES FLOW-DEPENDENT EPIGENETIC REGULATION OF ENDOTHELIAL GENE EXPRESSION, AND ALSO SUGGESTS THAT TARGETING THE EZH2/H3K27ME3/IGFBP5 PATHWAY MAY OFFER NOVEL THERAPEUTICS FOR INFLAMMATORY DISORDERS SUCH AS ATHEROSCLEROSIS. 2018 15 4497 33 MORPHINE LEADS TO GLOBAL GENOME CHANGES IN H3K27ME3 LEVELS VIA A POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) SELF-REGULATORY MECHANISM IN MESCS. BACKGROUND: ENVIRONMENTALLY INDUCED EPIGENETIC CHANGES CAN LEAD TO HEALTH PROBLEMS OR DISEASE, BUT THE MECHANISMS INVOLVED REMAIN UNCLEAR. MORPHINE CAN PASS THROUGH THE PLACENTAL BARRIER LEADING TO ABNORMAL EMBRYO DEVELOPMENT. HOWEVER, THE MECHANISM BY WHICH MORPHINE CAUSES THESE EFFECTS AND HOW THEY SOMETIMES PERSIST INTO ADULTHOOD IS NOT WELL KNOWN. TO UNRAVEL THE MORPHINE-INDUCED CHROMATIN ALTERATIONS INVOLVED IN ABERRANT EMBRYO DEVELOPMENT, WE EXPLORED THE ROLE OF THE H3K27ME3/PRC2 REPRESSIVE COMPLEX IN GENE EXPRESSION AND ITS TRANSMISSION ACROSS CELLULAR GENERATIONS IN RESPONSE TO MORPHINE. RESULTS: USING MOUSE EMBRYONIC STEM CELLS AS A MODEL SYSTEM, WE FOUND THAT CHRONIC MORPHINE TREATMENT INDUCES A GLOBAL DOWNREGULATION OF THE HISTONE MODIFICATION H3K27ME3. CONVERSELY, CHIP-SEQ SHOWED A REMARKABLE INCREASE IN H3K27ME3 LEVELS AT SPECIFIC GENOMIC SITES, PARTICULARLY PROMOTERS, DISRUPTING SELECTIVE TARGET GENES RELATED TO EMBRYO DEVELOPMENT, CELL CYCLE AND METABOLISM. THROUGH A SELF-REGULATORY MECHANISM, MORPHINE DOWNREGULATED THE TRANSCRIPTION OF PRC2 COMPONENTS RESPONSIBLE FOR H3K27ME3 BY ENRICHING HIGH H3K27ME3 LEVELS AT THE PROMOTER REGION. DOWNREGULATION OF PRC2 COMPONENTS PERSISTED FOR AT LEAST 48 H (4 CELL CYCLES) FOLLOWING MORPHINE REMOVAL, THOUGH PROMOTER H3K27ME3 LEVELS RETURNED TO CONTROL LEVELS. CONCLUSIONS: MORPHINE INDUCES TARGETING OF THE PRC2 COMPLEX TO SELECTED PROMOTERS, INCLUDING THOSE OF PRC2 COMPONENTS, LEADING TO CHARACTERISTIC CHANGES IN GENE EXPRESSION AND A GLOBAL REDUCTION IN H3K27ME3. FOLLOWING MORPHINE REMOVAL, ENHANCED PROMOTER H3K27ME3 LEVELS REVERT TO NORMAL SOONER THAN GLOBAL H3K27ME3 OR PRC2 COMPONENT TRANSCRIPT LEVELS. WE SUGGEST THAT H3K27ME3 IS INVOLVED IN INITIATING MORPHINE-INDUCED CHANGES IN GENE EXPRESSION, BUT NOT IN THEIR MAINTENANCE. MODEL OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) AND H3K27ME3 ALTERATIONS INDUCED BY CHRONIC MORPHINE EXPOSURE. MORPHINE INDUCES H3K27ME3 ENRICHMENT AT PROMOTERS OF GENES ENCODING CORE MEMBERS OF THE PRC2 COMPLEX AND IS ASSOCIATED WITH THEIR TRANSCRIPTIONAL DOWNREGULATION. 2020 16 5995 20 TGFBETA-INDUCED FIBROBLAST ACTIVATION REQUIRES PERSISTENT AND TARGETED HDAC-MEDIATED GENE REPRESSION. TISSUE FIBROSIS IS A CHRONIC DISEASE DRIVEN BY PERSISTENT FIBROBLAST ACTIVATION THAT HAS RECENTLY BEEN LINKED TO EPIGENETIC MODIFICATIONS. HERE, WE SCREENED A SMALL LIBRARY OF EPIGENETIC SMALL-MOLECULE MODULATORS TO IDENTIFY COMPOUNDS CAPABLE OF INHIBITING OR REVERSING TGFBETA-MEDIATED FIBROBLAST ACTIVATION. WE IDENTIFIED PRACINOSTAT, AN HDAC INHIBITOR, AS A POTENT ATTENUATOR OF LUNG FIBROBLAST ACTIVATION AND CONFIRMED ITS EFFICACY IN PATIENT-DERIVED FIBROBLASTS ISOLATED FROM FIBROTIC LUNG TISSUE. MECHANISTICALLY, WE FOUND THAT HDAC-DEPENDENT TRANSCRIPTIONAL REPRESSION WAS AN EARLY AND ESSENTIAL EVENT IN TGFBETA-MEDIATED FIBROBLAST ACTIVATION. TREATMENT OF LUNG FIBROBLASTS WITH PRACINOSTAT BROADLY ATTENUATED TGFBETA-MEDIATED EPIGENETIC REPRESSION AND PROMOTED FIBROBLAST QUIESCENCE. WE CONFIRMED A SPECIFIC ROLE FOR HDAC-DEPENDENT HISTONE DEACETYLATION IN THE PROMOTER REGION OF THE ANTI-FIBROTIC GENE PPARGC1A (PGC1ALPHA) IN RESPONSE TO TGFBETA STIMULATION. FINALLY, WE IDENTIFIED HDAC7 AS A KEY FACTOR WHOSE SIRNA-MEDIATED KNOCKDOWN ATTENUATES FIBROBLAST ACTIVATION WITHOUT ALTERING GLOBAL HISTONE ACETYLATION. TOGETHER, THESE RESULTS PROVIDE NOVEL MECHANISTIC INSIGHT INTO THE ESSENTIAL ROLE HDACS PLAY IN TGFBETA-MEDIATED FIBROBLAST ACTIVATION VIA TARGETED GENE REPRESSION. 2019 17 695 28 BRG1 IN THE NUCLEUS ACCUMBENS REGULATES COCAINE-SEEKING BEHAVIOR. BACKGROUND: DRUG ADDICTION IS DEFINED AS A CHRONIC DISEASE CHARACTERIZED BY COMPULSIVE DRUG SEEKING AND EPISODES OF RELAPSE DESPITE PROLONGED PERIODS OF DRUG ABSTINENCE. NEUROBIOLOGICAL ADAPTATIONS, INCLUDING TRANSCRIPTIONAL AND EPIGENETIC ALTERATIONS IN THE NUCLEUS ACCUMBENS, ARE THOUGHT TO CONTRIBUTE TO THIS LIFE-LONG DISEASE STATE. WE PREVIOUSLY DEMONSTRATED THAT THE TRANSCRIPTION FACTOR SMAD3 IS INCREASED AFTER 7 DAYS OF WITHDRAWAL FROM COCAINE SELF-ADMINISTRATION. HOWEVER, IT IS STILL UNKNOWN WHICH ADDITIONAL FACTORS PARTICIPATE IN THE PROCESS OF CHROMATIN REMODELING AND FACILITATE THE BINDING OF SMAD3 TO PROMOTER REGIONS OF TARGET GENES. HERE, WE EXAMINED THE POSSIBLE INTERACTION OF BRG1-ALSO KNOWN AS SMARCA4, AN ADENOSINE TRIPHOSPHATASE-CONTAINING CHROMATIN REMODELER-AND SMAD3 IN RESPONSE TO COCAINE EXPOSURE. METHODS: THE EXPRESSION OF BRG1, AS WELL AS ITS BINDING TO SMAD3 AND TARGET GENE PROMOTER REGIONS, WAS EVALUATED IN THE NUCLEUS ACCUMBENS AND DORSAL STRIATUM OF RATS USING WESTERN BLOTTING, CO-IMMUNOPRECIPITATION, AND CHROMATIN IMMUNOPRECIPITATION FOLLOWING ABSTINENCE FROM COCAINE SELF-ADMINISTRATION. RATS WERE ASSESSED FOR COCAINE-SEEKING BEHAVIORS AFTER EITHER INTRA-ACCUMBAL INJECTIONS OF THE BRG1 INHIBITOR PFI3 OR VIRAL-MEDIATED OVEREXPRESSION OF BRG1. RESULTS: AFTER WITHDRAWAL FROM COCAINE SELF-ADMINISTRATION, BRG1 EXPRESSION AND COMPLEX FORMATION WITH SMAD3 ARE INCREASED IN THE NUCLEUS ACCUMBENS, RESULTING IN INCREASED BINDING OF BRG1 TO THE PROMOTER REGIONS OF CTNNB1, MEF2D, AND DBN1. INTRA-ACCUMBAL INFUSION OF PFI3 ATTENUATED, WHEREAS VIRAL OVEREXPRESSION OF BRG1 ENHANCED, COCAINE-REINSTATEMENT BEHAVIOR. CONCLUSIONS: BRG1 IS A KEY MEDIATOR OF THE SMAD3-DEPENDENT REGULATION OF CELLULAR AND BEHAVIORAL PLASTICITY THAT MEDIATES COCAINE SEEKING AFTER A PERIOD OF WITHDRAWAL. 2016 18 1906 31 ENHANCER OF ZESTE HOMOLOG 2-CATALYSED H3K27 TRIMETHYLATION PLAYS A KEY ROLE IN ACUTE-ON-CHRONIC LIVER FAILURE VIA TNF-MEDIATED PATHWAY. ACUTE-ON-CHRONIC LIVER FAILURE IS MAINLY DUE TO HOST IMMUNITY SELF-DESTRUCTION. THE HISTONE H3 LYSINE 27 (H3K27) TRIMETHYLATING ENZYME, ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MEDIATES EPIGENETIC SILENCING OF GENE EXPRESSION AND REGULATES IMMUNITY, ALSO INVOLVES PATHOGENESIS OF SEVERAL LIVER DISEASES. THE CURRENT STUDY WAS TO DETERMINE THE ROLE OF METHYLTRANSFERASE EZH2 AND ITS CATALYSED H3K27 TRIMETHYLATION (H3K27ME3) IN LIVER FAILURE, AND TO FURTHER INVESTIGATE THE POTENTIAL TARGET FOR LIVER FAILURE TREATMENT. EZH2 AND ITS CATALYSED H3K27ME3 WERE DETERMINED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM LIVER FAILURE PATIENTS AND KUPFFER CELLS FROM EXPERIMENTAL MICE. FURTHERMORE, GSK126 (AN INHIBITOR FOR EZH2 TRIMETHYLATION FUNCTION) WAS APPLIED IN LIVER FAILURE MICE IN VIVO, AND LIPOPOLYSACCHARIDE-STIMULATED MONONUCLEAR CELLS IN VITRO. EZH2 AND H3K27ME3 WERE SIGNIFICANTLY UPREGULATED IN HUMAN PBMC FROM LIVER FAILURE PATIENTS OR MURINE KUPFFER CELLS FROM THE LIVER FAILURE ANIMALS, RESPECTIVELY. GSK126 AMELIORATED DISEASE SEVERITY IN LIVER FAILURE MICE, WHICH MAYBE ATTRIBUTE TO DOWN-REGULATE CIRCULATING AND HEPATIC PROINFLAMMATORY CYTOKINES, ESPECIALLY TNF VIA REDUCING H3K27ME3. IN-DEPTH CHROMATIN IMMUNOPRECIPITATION ANALYSIS UNRAVELLED THAT DECREASED ENRICHMENT OF H3K27ME3 ON TNF PROMOTOR, RESULTING IN TNF ELEVATION IN KUPFFER CELLS FROM LIVER FAILURE MICE. NUCLEAR FACTOR KAPPA B (NF-KAPPAB) AND PROTEIN KINASE B (AKT) SIGNALLING PATHWAYS WERE ACTIVATED UPON LIPOPOLYSACCHARIDE STIMULATION, BUT ATTENUATED BY USING GSK126, ACCOMPANIED WITH DECREASED TNF IN VITRO. IN CONCLUSION, EZH2 AND H3K27ME3 CONTRIBUTED TO THE PATHOGENESIS OF LIVER FAILURE VIA TRIGGERING TNF AND OTHER INDISPENSABLE PROINFLAMMATORY CYTOKINES. EZH2 WAS TO MODIFY H3K27ME3 ENRICHMENT, AS WELL AS, ACTIVATION OF THE DOWNSTREAM NF-KAPPAB AND AKT SIGNALLING PATHWAYS. 2018 19 4159 30 MECP2 CONTROLS AN EPIGENETIC PATHWAY THAT PROMOTES MYOFIBROBLAST TRANSDIFFERENTIATION AND FIBROSIS. BACKGROUND & AIMS: MYOFIBROBLAST TRANSDIFFERENTIATION GENERATES HEPATIC MYOFIBROBLASTS, WHICH PROMOTE LIVER FIBROGENESIS. THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARGAMMA) IS A NEGATIVE REGULATOR OF THIS PROCESS. WE INVESTIGATED EPIGENETIC REGULATION OF PPARGAMMA AND MYOFIBROBLAST TRANSDIFFERENTIATION. METHODS: CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAYS ASSESSED THE BINDING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) TO PPARGAMMA AND CHROMATIN MODIFICATIONS THAT SILENCE THIS GENE. MECP2(-/Y) MICE AND AN INHIBITOR (DZNEP) OF THE EPIGENETIC REGULATORY PROTEIN EZH2 WERE USED IN THE CARBON TETRACHLORIDE MODEL OF LIVER FIBROSIS. LIVER TISSUES FROM MICE WERE ASSESSED BY HISTOLOGIC ANALYSIS; MARKERS OF FIBROSIS WERE MEASURED BY QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR). REVERSE TRANSCRIPTION PCR DETECTED CHANGES IN EXPRESSION OF THE MICRORNA MIR132 AND ITS TARGET, ELONGATED TRANSCRIPTS OF MECP2. MYOFIBROBLASTS WERE TRANSFECTED WITH MIR132; PPARGAMMA AND MECP2 EXPRESSIONS WERE ANALYZED BY QPCR OR IMMUNOBLOTTING. RESULTS: MYOFIBROBLAST TRANSDIFFERENTIATION OF HEPATIC STELLATE CELLS IS CONTROLLED BY A COMBINATION OF MECP2, EZH2, AND MIR132 IN A RELAY PATHWAY. THE PATHWAY IS ACTIVATED BY DOWN-REGULATION OF MIR132, RELEASING THE TRANSLATIONAL BLOCK ON MECP2. MECP2 IS RECRUITED TO THE 5' END OF PPARGAMMA, WHERE IT PROMOTES METHYLATION BY H3K9 AND RECRUITS THE TRANSCRIPTION REPRESSOR HP1ALPHA. MECP2 ALSO STIMULATES EXPRESSION OF EZH2 AND METHYLATION OF H3K27 TO FORM A REPRESSIVE CHROMATIN STRUCTURE IN THE 3' EXONS OF PPARGAMMA. GENETIC AND PHARMACOLOGIC DISRUPTIONS OF MECP2 OR EZH2 REDUCED THE FIBROGENIC CHARACTERISTICS OF MYOFIBROBLASTS AND ATTENUATED FIBROGENESIS. CONCLUSIONS: LIVER FIBROSIS IS REGULATED BY AN EPIGENETIC RELAY PATHWAY THAT INCLUDES MECP2, EZH2, AND MIR132. REAGENTS THAT INTERFERE WITH THIS PATHWAY MIGHT BE DEVELOPED TO REDUCE FIBROGENESIS IN CHRONIC LIVER DISEASE. 2010 20 6517 21 TRANSCRIPTIONAL AND EPIGENETIC MECHANISMS OF ADDICTION. INVESTIGATIONS OF LONG-TERM CHANGES IN BRAIN STRUCTURE AND FUNCTION THAT ACCOMPANY CHRONIC EXPOSURE TO DRUGS OF ABUSE SUGGEST THAT ALTERATIONS IN GENE REGULATION CONTRIBUTE SUBSTANTIALLY TO THE ADDICTIVE PHENOTYPE. HERE, WE REVIEW MULTIPLE MECHANISMS BY WHICH DRUGS ALTER THE TRANSCRIPTIONAL POTENTIAL OF GENES. THESE MECHANISMS RANGE FROM THE MOBILIZATION OR REPRESSION OF THE TRANSCRIPTIONAL MACHINERY - INCLUDING THE TRANSCRIPTION FACTORS DELTAFOSB, CYCLIC AMP-RESPONSIVE ELEMENT BINDING PROTEIN (CREB) AND NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) - TO EPIGENETICS - INCLUDING ALTERATIONS IN THE ACCESSIBILITY OF GENES WITHIN THEIR NATIVE CHROMATIN STRUCTURE INDUCED BY HISTONE TAIL MODIFICATIONS AND DNA METHYLATION, AND THE REGULATION OF GENE EXPRESSION BY NON-CODING RNAS. INCREASING EVIDENCE IMPLICATES THESE VARIOUS MECHANISMS OF GENE REGULATION IN THE LASTING CHANGES THAT DRUGS OF ABUSE INDUCE IN THE BRAIN, AND OFFERS NOVEL INROADS FOR ADDICTION THERAPY. 2011